FPH Confirms no Material Impact on Earnings Guidance

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

FISHER & PAYKEL HEALTHCARE CONFIRMS NO MATERIAL IMPACT ON EARNINGS
GUIDANCE
Auckland, New Zealand, 21 February 2019 - Fisher & Paykel Healthcare announced today that
settlement of the global patent infringement litigation with ResMed will not have a material impact
on its net profit after tax guidance for the 2019 financial year.

The company provided earnings guidance in an announcement to the market on 26 November
2018 and the company expects no material impact to that guidance given the proximity of the
settlement to the end of the company’s financial year and the legal fees expected to be incurred to
withdraw the pending infringement cases.

More detail regarding the settlement of the global patent infringement litigation is available in the
company’s corresponding press release.


About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and
systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep
apnea. The company’s products are sold in over 120 countries worldwide. For more information
about the company, visit our website www.fphcare.com
.

Ends

Contact:
Investors and Media:
Marcus Driller
VP Corporate
marcus.driller@fphcare.co.nz
+64 (0) 27 578 9663